BioCentury
ARTICLE | Clinical News

Nelipepimut-S: Phase IIb started

March 18, 2013 7:00 AM UTC

Galena disclosed in its 2012 earnings that investigators began a single-blind, placebo-controlled Phase IIb trial to compare intradermal NeuVax plus Herceptin trastuzumab given every 3 weeks for 1 year vs. Herceptin plus granulocyte macrophage colony-stimulating factor (GM-CSF) in about 300 patients with HER2-expressing breast cancer who are disease-free after standard-of-care therapy. After completing the third Herceptin infusion, patients in the NeuVax arm will receive the vaccine every 3 weeks for 6 vaccinations. Galena (formerly RXi Pharmaceuticals Corp.) gained NeuVax through its acquisition of Apthera Inc. in 2011 (see BioCentury, April 18, 2011). ...